Brief: Emergent Biosolutions And Substipharm Biologics Announce Strategic Manufacturing Partnership To Support Japanese Encephalitis Vaccine In The United States
28/04/2026 14:36
April 28 (Reuters) - Emergent BioSolutions Inc EBS.N: EMERGENT BIOSOLUTIONS AND SUBSTIPHARM BIOLOGICS ANNOUNCE STRATEGIC MANUFACTURING PARTNERSHIP TO SUPPORT JAPANESE ENCEPHALITIS VACCINE IN THE UNITED STATES EMERGENT BIOSOLUTIONS INC - ENTERS $34.5 MILLION AGREEMENT WITH SUBSTIPHARM FOR JE VACCINE MANUFACTURING AND U.S. DISTRIBUTION EMERGENT BIOSOLUTIONS INC - CANTON FACILITY TO MANUFACTURE DRUG SUBSTANCE AND OBTAIN EXCLUSIVE DISTRIBUTION RIGHTS EMERGENT BIOSOLUTIONS INC - TO BE EXCLUSIVE DISTRIBUTOR OF JE VACCINE TO U.S. GOVERNMENT UPON FDA APPROVAL Source text: ID:nGNX9j3tq5 Further company coverage: EBS.N ((Reuters.Briefs@thomsonreuters.com;))